GlaxoSmithKline (GSK) has reportedly made an offer of $460 million to settle approximately 10,000 product liability suits over its diabetes drug Avandia, while the company is simultaneously defending the fate of the controversial pill at an FDA panel committee meeting.
While a GlaxoSmithKline spokeswoman told Cardiovascular Business News the company couldn’t comment directly about ongoing litigation, she acknowledged that a trial that was scheduled for June has been settled. Also, she confirmed the company will be headed to federal court in October. However, the company issued a press release acknowledging that it had settled some product liability cases regarding Avandia and other products.
The Miller Firm, a Washington, D.C.-based law firm that claims to represent the plaintiffs on its website, stated it has reached a settlement with GSK, after a “three-year struggle.”
Michael J. Miller, JD, founding partner of the Miller Firm, said the firm is “busily preparing letters” that will be sent to the plaintiffs, “explaining the pros and cons of this settlement offer,” along with recommending the offer to their clients. “Before we recommended the settlement … we thought about it a long time to make sure it was in your best interest,” he said in a video recording.